Literature DB >> 20438613

Acetyl-L-carnitine ameliorates mitochondrial dysfunction following contusion spinal cord injury.

Samir P Patel1, Patrick G Sullivan, Travis S Lyttle, Alexander G Rabchevsky.   

Abstract

In the present study, we evaluated the therapeutic efficacy of acetyl-l-carnitine (ALC) administration on mitochondrial dysfunction following tenth thoracic level contusion spinal cord injury (SCI) in rats. Initial results from experiments in vitro with naïve mitochondria showed that, in the absence of pyruvate, ALC can be used as an alternative substrate for mitochondrial respiration. Additionally, when added in vitro to mitochondria isolated from 24 h injured cords, ALC restored respiration rates to normal levels. For administration studies in vivo, injured rats were given i.p. injections of saline (vehicle) or ALC (300 mg/kg) at 15, 30 or 60 min post-injury, followed by one booster after 6 h. Mitochondria were isolated 24 h post-injury and assessed for respiration rates, activities of NADH dehydrogenase, cytochrome c oxidase and pyruvate dehydrogenase. SCI significantly (p < 0.05) decreased respiration rates and activities of all enzyme complexes, but ALC treatment significantly (p < 0.05) maintained mitochondrial respiration and enzyme activities compared with vehicle treatment. Critically, ALC administration in vivo at 15 min and 6 h post-injury versus vehicle, followed once daily for 7 days, significantly (p < 0.05) spared gray matter. In summary, ALC treatment maintains mitochondrial bioenergetics following contusion SCI and, thus, holds great potential as a neuroprotective therapy for acute SCI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20438613      PMCID: PMC2897952          DOI: 10.1111/j.1471-4159.2010.06764.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  69 in total

1.  Acetyl-1-carnitine. 2: Effects on learning and memory performance of aged rats in simple and complex mazes.

Authors:  C A Barnes; A L Markowska; D K Ingram; H Kametani; E L Spangler; V J Lemken; D S Olton
Journal:  Neurobiol Aging       Date:  1990 Sep-Oct       Impact factor: 4.673

2.  Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy.

Authors:  Peter B Rosenthal; Richard Henderson
Journal:  J Mol Biol       Date:  2003-10-31       Impact factor: 5.469

3.  Spectrophotometric assay of cytochrome c oxidase.

Authors:  L SMITH
Journal:  Methods Biochem Anal       Date:  1955

Review 4.  Neuroprotection and acute spinal cord injury: a reappraisal.

Authors:  Edward D Hall; Joe E Springer
Journal:  NeuroRx       Date:  2004-01

5.  Acetyl-L-carnitine: a drug able to slow the progress of Alzheimer's disease?

Authors:  A Carta; M Calvani
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

6.  Clinical pharmacodynamics of acetyl-L-carnitine in patients with Parkinson's disease.

Authors:  F M Puca; S Genco; L M Specchio; B Brancasi; R D'Ursi; A Prudenzano; A Miccoli; R Scarcia; R Martino; M Savarese
Journal:  Int J Clin Pharmacol Res       Date:  1990

7.  Analysis of age-associated changes in mitochondrial free radical generation by rat testis.

Authors:  Martha E Vázquez-Memije; Ruth Capin; Adela Tolosa; Mohammed El-Hafidi
Journal:  Mol Cell Biochem       Date:  2007-09-06       Impact factor: 3.396

8.  Neuroprotective effects of acetyl-L-carnitine on neuropathic pain and apoptosis: a role for the nicotinic receptor.

Authors:  Lorenzo Di Cesare Mannelli; Carla Ghelardini; Menotti Calvani; Raffaella Nicolai; Luigi Mosconi; Annarita Toscano; Alessandra Pacini; Alessandro Bartolini
Journal:  J Neurosci Res       Date:  2009-01       Impact factor: 4.164

9.  Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial.

Authors:  Valentina Tomassini; Carlo Pozzilli; Emanuela Onesti; Patrizio Pasqualetti; Fabiana Marinelli; Angela Pisani; Cesare Fieschi
Journal:  J Neurol Sci       Date:  2004-03-15       Impact factor: 3.181

10.  Acetyl-L-carnitine protects against amyloid-beta neurotoxicity: roles of oxidative buffering and ATP levels.

Authors:  Sirakarnt Dhitavat; Daniela Ortiz; Thomas B Shea; Ezequiel R Rivera
Journal:  Neurochem Res       Date:  2002-06       Impact factor: 3.996

View more
  40 in total

Review 1.  Vitamins and nutrients as primary treatments in experimental brain injury: Clinical implications for nutraceutical therapies.

Authors:  Cole Vonder Haar; Todd C Peterson; Kris M Martens; Michael R Hoane
Journal:  Brain Res       Date:  2015-12-23       Impact factor: 3.252

Review 2.  Targeting mitochondrial function for the treatment of acute spinal cord injury.

Authors:  Melanie L McEwen; Patrick G Sullivan; Alexander G Rabchevsky; Joe E Springer
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

3.  Pioglitazone treatment following spinal cord injury maintains acute mitochondrial integrity and increases chronic tissue sparing and functional recovery.

Authors:  Samir P Patel; David H Cox; Jenna L Gollihue; William M Bailey; Werner J Geldenhuys; John C Gensel; Patrick G Sullivan; Alexander G Rabchevsky
Journal:  Exp Neurol       Date:  2017-03-30       Impact factor: 5.330

4.  Acetyl-L-carnitine treatment following spinal cord injury improves mitochondrial function correlated with remarkable tissue sparing and functional recovery.

Authors:  S P Patel; P G Sullivan; T S Lyttle; D S K Magnuson; A G Rabchevsky
Journal:  Neuroscience       Date:  2012-03-15       Impact factor: 3.590

5.  5-hydroxytryptamine 1F Receptor Agonist Induces Mitochondrial Biogenesis and Promotes Recovery from Spinal Cord Injury.

Authors:  Epiphani C Simmons; Natalie E Scholpa; Kristan H Cleveland; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2019-11-27       Impact factor: 4.030

6.  Effects of Mitochondrial Transplantation on Bioenergetics, Cellular Incorporation, and Functional Recovery after Spinal Cord Injury.

Authors:  Jenna L Gollihue; Samir P Patel; Khalid C Eldahan; David H Cox; Renee R Donahue; Bradley K Taylor; Patrick G Sullivan; Alexander G Rabchevsky
Journal:  J Neurotrauma       Date:  2018-04-30       Impact factor: 5.269

7.  Augmentation of normal and glutamate-impaired neuronal respiratory capacity by exogenous alternative biofuels.

Authors:  Melissa D Laird; Pascaline Clerc; Brian M Polster; Gary Fiskum
Journal:  Transl Stroke Res       Date:  2013-08-10       Impact factor: 6.829

Review 8.  Mitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases.

Authors:  Epiphani C Simmons; Natalie E Scholpa; Rick G Schnellmann
Journal:  Exp Neurol       Date:  2020-04-11       Impact factor: 5.330

9.  N-acetylcysteine amide preserves mitochondrial bioenergetics and improves functional recovery following spinal trauma.

Authors:  Samir P Patel; Patrick G Sullivan; Jignesh D Pandya; Glenn A Goldstein; Jenna L VanRooyen; Heather M Yonutas; Khalid C Eldahan; Johnny Morehouse; David S K Magnuson; Alexander G Rabchevsky
Journal:  Exp Neurol       Date:  2014-05-05       Impact factor: 5.330

10.  Pharmacological Stimulation of Mitochondrial Biogenesis Using the Food and Drug Administration-Approved β2-Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury.

Authors:  Natalie E Scholpa; Hannah Williams; Wenxue Wang; Daniel Corum; Aarti Narang; Stephen Tomlinson; Patrick G Sullivan; Alexander G Rabchevsky; Rick G Schnellmann
Journal:  J Neurotrauma       Date:  2018-11-16       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.